Iconovo AB (publ) (ICO.ST)
SEK 2.41
(-2.82%)
SEK 2.41
(-2.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -35.33 Million SEK | -12.78% |
| 2022 | -38.73 Million SEK | -86.33% |
| 2021 | -24.9 Million SEK | -58.45% |
| 2020 | -16.62 Million SEK | -49.11% |
| 2019 | -11.07 Million SEK | -251.98% |
| 2018 | -3.74 Million SEK | -164.85% |
| 2017 | 2.82 Million SEK | -6.43% |
| 2016 | 4.12 Million SEK | 496.87% |
| 2015 | -876.98 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -8.15 Million SEK | -15.9% |
| 2024 Q1 | -7.79 Million SEK | 5.21% |
| 2024 Q2 | -7.03 Million SEK | -2.94% |
| 2023 FY | - SEK | -12.78% |
| 2023 Q4 | -8.68 Million SEK | -18.98% |
| 2023 Q3 | -7.29 Million SEK | 30.19% |
| 2023 Q2 | -10.45 Million SEK | -1.26% |
| 2023 Q1 | -10.32 Million SEK | 26.76% |
| 2022 Q2 | -9.81 Million SEK | -33.75% |
| 2022 FY | - SEK | -86.33% |
| 2022 Q4 | -14.09 Million SEK | -87.51% |
| 2022 Q3 | -7.51 Million SEK | 23.42% |
| 2022 Q1 | -7.34 Million SEK | -6.72% |
| 2021 FY | - SEK | -58.45% |
| 2021 Q3 | -2.51 Million SEK | 52.46% |
| 2021 Q2 | -5.29 Million SEK | 13.38% |
| 2021 Q4 | -6.87 Million SEK | -173.15% |
| 2021 Q1 | -6.11 Million SEK | -118.54% |
| 2020 Q4 | -2.79 Million SEK | -133.56% |
| 2020 Q3 | -1.19 Million SEK | 75.7% |
| 2020 Q2 | -4.93 Million SEK | -17.16% |
| 2020 FY | - SEK | -49.11% |
| 2020 Q1 | -4.2 Million SEK | 38.32% |
| 2019 Q4 | -6.82 Million SEK | -405.32% |
| 2019 Q3 | -1.35 Million SEK | 38.33% |
| 2019 Q2 | -2.18 Million SEK | -364.69% |
| 2019 Q1 | 827 Thousand SEK | -65.79% |
| 2019 FY | - SEK | -251.98% |
| 2018 Q4 | 2.41 Million SEK | 258.64% |
| 2018 Q2 | 653 Thousand SEK | 116.12% |
| 2018 Q1 | -4.05 Million SEK | -179.15% |
| 2018 FY | - SEK | -164.85% |
| 2018 Q3 | -1.52 Million SEK | -333.38% |
| 2017 Q4 | 5.11 Million SEK | 298.49% |
| 2017 Q3 | -2.57 Million SEK | -248.33% |
| 2017 Q2 | 1.73 Million SEK | 249.57% |
| 2017 FY | - SEK | -6.43% |
| 2017 Q1 | -1.16 Million SEK | 0.0% |
| 2016 FY | - SEK | 496.87% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 54.182% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 108.579% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 108.579% |
| Arcoma AB | 6.24 Million SEK | 665.548% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 60.731% |
| BICO Group AB (publ) | 322.3 Million SEK | 110.964% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 153.556% |
| CellaVision AB (publ) | 207.24 Million SEK | 117.05% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 48.344% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -26.456% |
| C-Rad AB (publ) | 48.9 Million SEK | 172.255% |
| Duearity AB (publ) | -24.77 Million SEK | -42.602% |
| Dignitana AB (publ) | -264 Thousand SEK | -13284.646% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 59.709% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.596% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 47.457% |
| Integrum AB (publ) | 8.76 Million SEK | 503.302% |
| Luxbright AB (publ) | -23.86 Million SEK | -48.053% |
| Mentice AB (publ) | 28.87 Million SEK | 222.382% |
| OssDsign AB (publ) | -122.02 Million SEK | 71.041% |
| Paxman AB (publ) | 31.22 Million SEK | 213.15% |
| Promimic AB (publ) | -3.68 Million SEK | -859.161% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 76.522% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 31.823% |
| ScandiDos AB (publ) | -13.35 Million SEK | -164.566% |
| Sectra AB (publ) | 615.06 Million SEK | 105.745% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 31.618% |
| Senzime AB (publ) | -118.82 Million SEK | 70.262% |
| SpectraCure AB (publ) | -20.96 Million SEK | -68.513% |
| Stille AB | 56.04 Million SEK | 163.053% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 98.891% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 127.917% |